Lexicon Pharmaceuticals Inc. announced that clinical data on the effect of sotagliflozin on adipose tissue distribution in non-diabetic patients will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025), scheduled for December 8-10, 2025, in Washington, D.C. The data are derived from the SOTA-P-CARDIA trial, a prospective, randomized, double-blind, placebo-controlled study enrolling patients with heart failure with preserved ejection fraction (HFpEF) and conducted by Mount Sinai Medical Center. The presentation, titled "Effect of sotagliflozin on adipose distribution in non-diabetic patients with HFpEF," will be delivered by Juan Jose Badimon, Ph.D., on December 8, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597526-en) on December 05, 2025, and is solely responsible for the information contained therein.